Bioplatin AG is a trading company dealing in various commodities, particularly pharmaceutical and medical products, and in the acquisition and use of licences. Its principal project is Dicycloplatin (DCP), a platinum‑based anti‑tumour agent described on the website with Phase I clinical information and patent protection in multiple markets.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Anti-tumor agent based on platinum for the treatment of cancer cells; described as a new active ingredient for bronchial carcinoma and liver cancer, with Phase I results and low toxicity.
DCP patent and licence rights
Acquisition and use of licence and protection rights for DCP; worldwide patent protection is mentioned, as well as interest from pharmaceutical companies in an in-licensing.
Knowledge
No knowledge articles yet
Once Bioplatin AG has claimed this profile, we'll publish editorial articles and case studies here together.